This inventor holds 2 USPTO granted patents. Top assignees: Welfide Corporation, Yoshitomi Pharmaceutical Industries, Ltd.. Active years: 2000-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2001
Title: Nobuharu Goto: Innovator in Diabetic Complications Treatment
Introduction
Nobuharu Goto is a notable inventor based in Iruma, Japan. He has made significant contributions to the field of medicine, particularly in the treatment and prophylaxis of diabetic complications. With a total of 2 patents to his name, Goto's work has the potential to impact many lives.
Latest Patents
One of Goto's latest patents is titled "Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives." This invention relates to an agent that comprises 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid as an active ingredient. The compound is designed to be effective in preventing and treating various diabetic complications, including diabetic neuropathy, nephropathy, ophthalmopathy, and arteriosclerosis. The medicament is noted for its long-lasting effects, requiring only small doses and a single daily administration.
Career Highlights
Throughout his career, Nobuharu Goto has worked with reputable companies such as Welfide Corporation and Yoshitomi Pharmaceutical Industries, Ltd. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.
Collaborations
Goto has collaborated with various professionals in his field, including his coworker Yoshiharu Hayashi. These partnerships have likely enhanced his research and development efforts.
Conclusion
Nobuharu Goto is a distinguished inventor whose work in diabetic complications treatment showcases his innovative spirit and dedication to improving healthcare. His contributions are poised to make a significant difference in the lives of those affected by diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile